Cathie Wood of Ark Invest remains bullish on Tesla and other game-changing companies, even when Wall Street analysts are not. Wood’s strategy of buying cheap players for long-term growth has led Ark Innovation to climb over 100% in the past three years, outperforming the S&P 500.

Wood has been adding to her holdings of CRISPR Therapeutics, a biotech company specializing in gene editing. Wood purchased shares in both Ark Innovation and her healthcare fund, with CRISPR Therapeutics now a significant position in both funds.

CRISPR Therapeutics recently achieved a milestone with the approval of its blood disorder treatment, Casgevy, showcasing the potential of its gene-editing technology. The company is also advancing other candidates through clinical trials, with positive results for CTX310 in reducing heart disease risk factors.

Although CRISPR Therapeutics’ stock has seen double-digit declines in recent years, the company’s growth potential remains strong with revenue expected from Casgevy and positive clinical trial results. Cathie Wood’s increased investment in the company signals confidence in its future prospects.

Investors considering CRISPR Therapeutics should weigh the potential for earnings growth and innovative gene-editing technology. While the stock was not included in the Motley Fool’s list of top 10 stocks, the company’s advancements in gene editing could lead to significant returns in the future.

Read more at Nasdaq: Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%